|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0016360,
umls-concept:C0023413,
umls-concept:C0025677,
umls-concept:C0030705,
umls-concept:C0036525,
umls-concept:C0040808,
umls-concept:C0282460,
umls-concept:C0443264,
umls-concept:C1511237,
umls-concept:C1522484,
umls-concept:C1527249,
umls-concept:C1550436,
umls-concept:C1705509
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2002-10-16
|
|
pubmed:abstractText |
In vitro, methotrexate (MTX) is the best modulator for bolus 5-fluorouracil (5FU), whereas folinic acid (FA) is the best for continuous infusion. We evaluated the effect of 5FU modulated by both MTX (bolus administration) and FA (continuous infusion) as second-line treatment of patients with metastatic colorectal cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0030-2414
|
|
pubmed:author |
pubmed-author:ArpinoGG,
pubmed-author:BiancoA RAR,
pubmed-author:CarlomagnoCC,
pubmed-author:CatalanoGG,
pubmed-author:CostanzoRR,
pubmed-author:De LaurentiisMM,
pubmed-author:De PlacidoSS,
pubmed-author:FerraraCC,
pubmed-author:LauriaRR,
pubmed-author:MassarelliEE,
pubmed-author:MilanoAA,
pubmed-author:Vernaglia LombardiAA
|
|
pubmed:copyrightInfo |
Copyright 2002 S. Karger AG, Basel
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
63
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
219-25
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12381900-Adenocarcinoma,
pubmed-meshheading:12381900-Adult,
pubmed-meshheading:12381900-Aged,
pubmed-meshheading:12381900-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12381900-Colorectal Neoplasms,
pubmed-meshheading:12381900-Diarrhea,
pubmed-meshheading:12381900-Disease Progression,
pubmed-meshheading:12381900-Fluorouracil,
pubmed-meshheading:12381900-Follow-Up Studies,
pubmed-meshheading:12381900-Humans,
pubmed-meshheading:12381900-Infusions, Intravenous,
pubmed-meshheading:12381900-Injections, Intravenous,
pubmed-meshheading:12381900-Leucovorin,
pubmed-meshheading:12381900-Methotrexate,
pubmed-meshheading:12381900-Middle Aged,
pubmed-meshheading:12381900-Nausea,
pubmed-meshheading:12381900-Neoplasm Staging,
pubmed-meshheading:12381900-Survival Rate,
pubmed-meshheading:12381900-Treatment Outcome,
pubmed-meshheading:12381900-Vomiting
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
|
|
pubmed:affiliation |
Division of Medical Oncology, Department of Molecular and Clinical Endocrinology and Oncology, University of Naples Federico II, Naples, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Clinical Trial, Phase II
|
